| scholarly article | Q13442814 |
| P2093 | author name string | Roger Abounader | |
| P2860 | cites work | Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 |
| Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 | ||
| Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells | Q24550891 | ||
| Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis | Q24683896 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines | Q28256046 | ||
| Targeting the tumor and its microenvironment by a dual-function decoy Met receptor | Q28272715 | ||
| Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering | Q28277010 | ||
| The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase | Q28280668 | ||
| A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family | Q28285975 | ||
| Regulation of c-Met-dependent gene expression by PTEN | Q28290742 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 | ||
| Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses | Q28513246 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs | Q28564702 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations | Q30416701 | ||
| Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy | Q30447803 | ||
| Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma | Q33370229 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance | Q34255631 | ||
| Genetics of nervous system tumors | Q34480154 | ||
| A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. | Q35285121 | ||
| Retroviral oncogenes and TOR. | Q35560403 | ||
| mTOR as a target for cancer therapy. | Q35560406 | ||
| Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells | Q35745875 | ||
| Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors | Q35810225 | ||
| Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme | Q36151836 | ||
| The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions | Q36232160 | ||
| Platelet-derived growth factor (PDGF) and glial tumorigenesis | Q36247732 | ||
| Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways | Q36256326 | ||
| Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. | Q36301565 | ||
| Class reunion: PTEN joins the nuclear crew. | Q36313163 | ||
| PTEN enters the nuclear age. | Q36705731 | ||
| Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations | Q36742629 | ||
| Lessons learned in the development of targeted therapy for malignant gliomas. | Q36874488 | ||
| Met and hepatocyte growth factor/scatter factor expression in human gliomas | Q36894692 | ||
| The nuclear affairs of PTEN. | Q37063858 | ||
| Tenets of PTEN tumor suppression | Q37154214 | ||
| Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group | Q38442782 | ||
| AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma | Q40236389 | ||
| Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells | Q40243368 | ||
| The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation | Q40254270 | ||
| Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells | Q40268565 | ||
| The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy | Q40360944 | ||
| Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis | Q40372916 | ||
| PTEN enters the nucleus by diffusion | Q40387100 | ||
| mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma | Q40407116 | ||
| Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation | Q40408804 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas | Q40519870 | ||
| Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. | Q40692658 | ||
| The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells | Q40993616 | ||
| Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth | Q41103718 | ||
| Scatter factor expression and regulation in human glial tumors | Q41184022 | ||
| Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. | Q42807109 | ||
| Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. | Q42813095 | ||
| Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel | Q43491437 | ||
| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib | Q43742602 | ||
| Cancer: survival pathways meet their end. | Q44804339 | ||
| PTEN gene mutations are seen in high-grade but not in low-grade gliomas | Q44846579 | ||
| Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer | Q45029660 | ||
| Mechanistic insights into maintenance of high p53 acetylation by PTEN. | Q46035699 | ||
| EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas | Q47867936 | ||
| Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. | Q48230264 | ||
| Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors | Q48303307 | ||
| Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme | Q48345191 | ||
| Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia | Q48373067 | ||
| Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas | Q48423939 | ||
| Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas | Q48475005 | ||
| Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops | Q48478557 | ||
| Platelet-derived Growth Factor and Its Receptor Expression in Human Oligodendrogliomas | Q48524373 | ||
| Somatic mutations of PTEN in glioblastoma multiforme | Q48618632 | ||
| In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis | Q48700301 | ||
| Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. | Q48727704 | ||
| Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo | Q48744988 | ||
| Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. | Q52180037 | ||
| Genetic alterations in primary glioblastomas in Japan. | Q54622826 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. | Q55474170 | ||
| Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. | Q55475281 | ||
| Restoration of wild-type PTEN expression leads to apoptosis, induces differentiation, and reduces telomerase activity in human glioma cells. | Q55476962 | ||
| Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans | Q55477950 | ||
| Phosphatidylinositol 3-kinase Contributes to Erk1/Erk2 MAP Kinase Activation Associated with Hepatocyte Growth Factor-induced Cell Scattering | Q58327398 | ||
| Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression | Q73004517 | ||
| PTEN and p53: who will get the upper hand? | Q73086898 | ||
| The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase | Q73816403 | ||
| PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells | Q81877328 | ||
| Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways | Q95717860 | ||
| P433 | issue | 2 | |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 235-245 | |
| P577 | publication date | 2009-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy | |
| P478 | volume | 9 |
| Q55462761 | A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. |
| Q27851995 | A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal |
| Q37397228 | Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q37643987 | Clinical management of uterine sarcomas |
| Q41861511 | Down-regulation of TERE1/UBIAD1 activated Ras–MAPK signalling and induced cell proliferation |
| Q44801430 | Downregulation of PTEN expression in psoriatic lesions |
| Q39251444 | Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors |
| Q30414265 | Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition |
| Q38618205 | Implications of mitogen-activated protein kinase signaling in glioma. |
| Q98782026 | Lens fiber cell differentiation occurs independently of fibroblast growth factor receptor signaling in the absence of Pten |
| Q54250883 | Nuclear factor-κB pathway activation and phosphatase and tensin homolog downregulation in psoriasis |
| Q49887901 | PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. |
| Q37638344 | Protein tyrosine phosphatases in glioma biology |
| Q38979328 | Regulation ofDrosophilaglial cell proliferation by Merlin-Hippo signaling |
| Q35140496 | Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis |
| Q48806296 | Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial |
| Q39385631 | Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor |
| Q35184491 | The BRAF kinase domain promotes the development of gliomas in vivo |
| Q35634042 | The Importance of 10q Status in an Outcomes-Based Comparison Between 1p/19q Fluorescence In Situ Hybridization and Polymerase Chain Reaction–Based Microsatellite Loss of Heterozygosity Analysis of Oligodendrogliomas |
| Q30428370 | The role of microRNAs in glioma initiation and progression |
Search more.